Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Shahin Nargesi, Zeinab Dolatshahi, Aziz Rezapour, Vahid Alipour, Aghdas Souresrafil, Hiro Farabi, Seyed Arash Javadmoosavi, Mandana Safakhah & Najmeh Moradi. (2022) Cost-effectiveness of osimertinib in the treatment of advanced EGFR-mutated non-small cell lung cancer: a systematic review. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 543-554.
Read now
Read now
J Aguilar-Serra, V Gimeno-Ballester, a Pastor-Clerigues, J Milara, C Trigo-Vicente & J Cortijo. (2022) Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer. Expert Review of Pharmacoeconomics & Outcomes Research 22:4, pages 637-646.
Read now
Read now
Fredrik O. L. Nilsson, Peter Gal, Ivan Houisse, Jasmina I. Ivanova & Sandra T. Asanin. (2021) The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (EGFRm NSCLC) in Sweden. Journal of Medical Economics 24:1, pages 447-457.
Read now
Read now
Nimer S. Alkhatib, Brian Erstad, Kenneth Ramos, Ali McBride, Sandipan Bhattacharjee, Marion Slack & Ivo Abraham. (2020) Pricing methods in outcome-based contracting: δ3: reference-based pricing. Journal of Medical Economics 23:11, pages 1230-1236.
Read now
Read now
Nimer S. Alkhatib, Kenneth Ramos, Brian Erstad, Marion Slack, Ali McBride, Sandipan Bhattacharjee & Ivo Abraham. (2020) Pricing methods in outcome-based contracting: δ1: cost effectiveness analysis and cost-utility analysis-based pricing. Journal of Medical Economics 23:11, pages 1215-1222.
Read now
Read now
Maobai Liu, Longfeng Zhang, Qishu Huang, Na Li, Bin Zheng & Hongfu Cai. (2019) Cost-Effectiveness Analysis Of Ceritinib And Alectinib Versus Crizotinib In The Treatment Of Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer. Cancer Management and Research 11, pages 9195-9202.
Read now
Read now
Sebastian Mondaca, Michael Offin, Laetitia Borsu, Mackenzie Myers, Sowmya Josyula, Alex Makhnin, Ronglai Shen, Gregory J. Riely, Charles M. Rudin, Marc Ladanyi, Helena A. Yu, Bob T. Li & Maria E. Arcila. (2019) Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers. Acta Oncologica 58:11, pages 1634-1639.
Read now
Read now
Articles from other publishers (13)
Jon Apple, Maral DerSarkissian, Anne Shah, Rose Chang, Yan Chen, Xuanhao He & Justin Chun. (2023) Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs. Journal of Comparative Effectiveness Research 12:11.
Crossref
Crossref
Xiwen Zhou, Jianting Du, Guobing Xu, Chun Chen, Bin Zheng & Jiahe Chen. (2022)
Cost‐effectiveness of osimertinib versus placebo in resected
EGFR
‐mutated non‐small cell lung cancer in China
. Cancer Medicine 11:23, pages 4449-4456.
Crossref
Crossref
Yamin Shu, Yufeng Ding, Xucheng He, Yanxin Liu, Pan Wu & Qilin Zhang. (2022) Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for EGFR-mutated advanced non-small-cell lung cancer in China. Frontiers in Pharmacology 13.
Crossref
Crossref
Xudong Zhang, Pingping Fang, Guangquan Su, Shuangying Gui & Aizong Shen. (2022) Cost–effectiveness of ensartinib for patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer in China. Journal of Comparative Effectiveness Research 11:12, pages 871-878.
Crossref
Crossref
Kyla H Thomas, Michael N Dalili, José A López-López, Edna Keeney, David Phillippo, Marcus R Munafò, Matt Stevenson, Deborah M Caldwell & Nicky J Welton. (2021) Smoking cessation medicines and e-cigarettes: a systematic review, network meta-analysis and cost-effectiveness analysis. Health Technology Assessment 25:59, pages 1-224.
Crossref
Crossref
Raymond Henderson, Peter Keeling, Declan French, Dave Smart, Richard Sullivan & Mark Lawler. (2021) Cost‐effectiveness of precision diagnostic testing for precision medicine approaches against non‐small‐cell lung cancer: A systematic review. Molecular Oncology 15:10, pages 2672-2687.
Crossref
Crossref
Vera Hirsh & Jaspal Singh. (2020) Optimal sequencing strategies in the treatment of EGFR mutation–positive non–small cell lung cancer: Clinical benefits and cost-effectiveness. American Journal of Health-System Pharmacy 77:18, pages 1466-1476.
Crossref
Crossref
Weiting Liao, Jiaxing Huang, David Hutton, Guiqi Zhu, Qiuji Wu, Feng Wen, Liangliang Bai & Qiu Li. (2019) Cost‐effectiveness analysis of cabozantinib as second‐line therapy in advanced hepatocellular carcinoma. Liver International 39:12, pages 2408-2416.
Crossref
Crossref
Javier Aguilar-Serra, Vicente Gimeno-Ballester, Alfonso Pastor-Clerigues, Javier Milara, Ezequiel Marti-Bonmati, Cristina Trigo-Vicente, Manuel Alós-Almiñana & Julio Cortijo. (2019) Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost–effectiveness analysis. Journal of Comparative Effectiveness Research 8:11, pages 853-863.
Crossref
Crossref
Bin Wu, Xiaohua Gu, Qiang Zhang & Feng Xie. (2019) Cost-Effectiveness of Osimertinib in Treating Newly Diagnosed, Advanced EGFR-Mutation-Positive Non-Small Cell Lung Cancer. The Oncologist 24:3, pages 349-357.
Crossref
Crossref
Zorawar S. Noor & Jonathan W. Goldman. 2019. Targeted Therapies for Lung Cancer. Targeted Therapies for Lung Cancer
1
30
.
Doreen A. Ezeife, Veronica Kirk, Derek S. Chew, Nancy A. Nixon, Roy Lee, Lisa W. Le, Kelvin K.-W. Chan & Natasha B. Leighl. (2018) Economic analysis of osimertinib in previously untreated EGFR-mutant advanced non-small cell lung cancer in Canada. Lung Cancer 125, pages 1-7.
Crossref
Crossref
Pedro N. AguiarJrJr, Benjamin Haaland, Wungki Park, Pui San Tan, Auro del Giglio & Gilberto de Lima LopesJrJr. (2018)
Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With
EGFR
-Mutated Advanced Non–Small Cell Lung Cancer
. JAMA Oncology 4:8, pages 1080.
Crossref
Crossref